Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by BridgeBio Pharma, Inc.
< Previous
1
2
3
Next >
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
April 07, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 20, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
March 05, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
March 04, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
March 04, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
February 22, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
February 07, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
February 05, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
February 02, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
January 18, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
January 10, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
January 10, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
January 03, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)
January 03, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia
December 13, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
December 05, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
November 12, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023
November 09, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 08, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update
November 02, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 11, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)
October 10, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
October 09, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
October 03, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces $250 Million Private Placement Equity Financing
September 25, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 08, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 07, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia
September 06, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.